HOME >> MEDICINE >> NEWS
Other highlights in the March 2 JNCI

ol of Public Health in Minneapolis, discusses two novel aspects of this study--comparing the offer of an explicit choice between screening tests to recommendations of a specific test and to the option of doing both tests, and comparing two methods of distributing the FOBT kits. He questions whether theoretical models of screening behavior would predict the surprising finding that subjects who were given a choice between screening methods did not have a higher screening participation rate than subjects who were not given a choice.

Contacts:

  • Article: Nereo Segnan, Centro Prevenzione Oncologica Regione Piemonte and Azienda Sanitaria Ospedaliera S Giovanni Battista, +390116333860, nereo.segnan@cpo.it
  • Editorial: Molly Portz, Media Relations, University of Minnesota, 612-625-2640, mportz@umn.edu

    Tamoxifen's Association With Endometrial Cancer Risk in Pre- and Postmenopausal Women Examined

    Tamoxifen use is associated with an increased risk of endometrial cancer. A new study has found that this risk is similar in pre- and postmenopausal women, increases with duration of use, and does not diminish through 5 years of follow-up after the treatment ends.

    Anthony J. Swerdlow, D.Sc., of the Institute of Cancer Research in Sutton, England, and colleagues conducted a casecontrol study in Britain of 813 patients who had endometrial cancer following breast cancer diagnosis and 1,067 control subjects who had breast cancer but not subsequent endometrial cancer.

    Overall, tamoxifen treatment was associated with 2.4 times the risk of endometrial cancer compared with no treatment. The risk increased with the duration of treatment and did not diminish in the 5 years following the end of treatment. The risk was similar in pre- and postmenopausal women. The authors write that, until further data are available, their results "suggest that the associated ris
    '"/>



  • Contact: Sarah L. Zielinski
    jncimedia@oupjournals.org
    301-841-1287
    Journal of the National Cancer Institute
    1-Mar-2005


    Page: 1 2 3 4

    Related medicine news :

    1. Other highlights in the March 16 JNCI
    2. Other highlights in the February 2 JNCI
    3. Other highlights in the January 19 JNCI
    4. Other highlights in the December 15 JNCI
    5. Other highlights in the December 1 JNCI
    6. Other highlights in the September 15 JNCI
    7. Other highlights in the April 21 JNCI
    8. Other highlights in the April 7 JNCI
    9. Other highlights in the January 7 issue of JNCI
    10. Other highlights in the December 3 issue of JNCI
    11. Other highlights in the November 19 issue of JNCI

    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    TAG: Other highlights the March JNCI

    (Date:8/1/2014)... New York (PRWEB) August 01, 2014 ... in the wake of the 2012 Rejuvenate and ... move forward in New Jersey’s Bergen County Superior ... filed in the proceeding, the Court has ... Confidentiality governing any and all hard copy and ...
    (Date:8/1/2014)... Summer is here, and with it comes the ... and they can be a pain for dogs. Animal Emergency ... their customers get rid of ticks and prevent them completely. ... the summer, which is why they are so active during ... woodland areas and carry a number of diseases, including lyme ...
    (Date:8/1/2014)... The American Telemedicine Association (ATA) lauds ... Peter Welch (D-VT), for their latest actions to ... of 2014, which improves telemedicine coverage in Medicare. ... healthcare access and affordability using telecommunications technology," said ... cost-saving provisions are critical to improve telehealth coverage ...
    (Date:8/1/2014)... 2014 The "Antimicrobial Coatings Market ... Zinc Oxide, Titanium Dioxide, and Zinc Omadine), Application ... Food & Beverages, Textiles, and others), & Geography ... Trends and Forecasts to 2018" analyzes the Antimicrobial ... and trends in the diverse geographical regions. , ...
    (Date:8/1/2014)... August 01, 2014 The North America ... security solutions market in North America with analysis and ... from around $3.53 billion in 2014 to $4.77 billion ... to 2019. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
    Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Tis the Season for Tick Prevention 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4
    (Date:7/31/2014)... SAN DIEGO, July 31, 2014  ResMed Inc. (NYSE: ... and for the fiscal year ended June 30, 2014.  Revenue ... quarter ended June 30, 2013 (a 1 percent decrease on ... increase of 20 percent compared to the quarter ended June ... $0.61, an increase of 22 percent compared to the quarter ...
    (Date:7/31/2014)... FRANCISCO, July 31, 2014 Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2014. Cash ... $301.4 million as compared to $309.1 million at March 31, ... for Nektar as we look forward to significant milestones for ... Robin, President and Chief Executive Officer of Nektar. "The first ...
    (Date:7/31/2014)... Mass. , July 31, 2014 /PRNewswire/ ... funding changes brought about by the Affordable ... reimbursement and prescribing of pharmaceutical therapies. The ... cover beneficiaries through new regulations and expanded ... occurring in the health exchanges—state-based marketplaces set ...
    Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4
    Cached News: